MedTrace Logo

A Neurofeedback Booster for Emotion Regulation Therapy

NCT04333888 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-03-11

No results posted yet for this study

Summary

This is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback will be administered to N=22 patients with BPD while they receive residential Dialectical Behavior Therapy treatment. In addition, outcomes are assessed from a control group with same sample size who do not receive the treatment.

Conditions

  • Borderline Personality Disorder

Interventions

BEHAVIORAL

Neurofeedback

fMRI neurofeedback training of amygdala downregulation

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • AE Foundation

    collaborator OTHER

  • Christian Paret

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-21
Primary Completion
2024-02-28
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333888 on ClinicalTrials.gov